Givosiran

Have these positions been filled? I’m still seeing them listed on the company’s website.

 

It’s obvious they don’t know what they are doing. Not a good sign for this type of role.

 

Run. Seriously just run away. Ethics are terrible and the home office has a true and visceral disdain for the commercial team. Read the other posts, its all true.

 

Guessing you are a rejected candidate - one of the best interview experiences I have ever had.

 

So we are to believe that you are a newly hired member of the Givo field force (a BAE, I'm assuming) and yet you know that the poster was a rejected candidate, and is lying about corporate disdain for the Givo commercial team. Yeh...that makes sense to me.

 

I spoke with a recruiter yesterday. She didn't even sound that thrilled. They wouldn't list the salary range. Bonus is at 50.

 

Alnylam will pay you a good salary, souls are expensive.

 

Most pharma companies collect souls. The question is...does the salary justify it?

 

why yes, yes it does.

 

Then you are perfect for the Asylum.

 

But..are these positions filled?

 

No. They are open and you can now join in on selling dangerous drugs for off-label use. Onpattro likely has significant cardiac issues and is being promoted almost exclusively to cardiologists. And this is what we have with Givo:

Givosiran's efficacy profile looks robust but its safety profile is materially worse than expected, SVB Leerink analyst Mani Foroohar said in a note.

Although the patients did have underlying liver disease which could have affected results, the large number of side effects among patients on the drug was still worrying, Foroohar added.

On a conference call, analysts questioned the drug's safety but Alnylam executives played down the concerns.

"Chronic administration of givosiran is very, very well tolerated, both from a kidney and liver perspective," Chief Medical Officer, Pushkal Garg said on the call.

How can drug both have significant serious side effects AND be “very, very well tolerated”? This company will do and say anything to make a dime.

 

There is no way you work for Alnylam, this is clearly amateur opposition "psy-ops" shit. The reality is that there have been very few discontinuations on the medication and when dealing with an incredibly sick population to start with, SAE's are going to happen.

 

You wish I wasn’t an insider but you’re wrong. Facts: Revusiran discontinued because it killed people. Then the company did not adequately report everything they knew and ruined relationships with KOLs. Patisiran had multiple deaths in Apollo due to cardiac issues. Givo does have significant side-effects and you’re denial of this is an example of how Alnylam has strayed off course due to the arrogance of our leadership. Where’s the fair balance? Why don’t we have a neurology promotional plan for a product only indicated for polyneuropathy? This is all real and a real problem. You either don’t care or are incapable of seeing the truths.

 

So-
1. Revusiran wasn't discontinued due to deaths, excess mortality wasn't noted until after discontinuation
2. Adequite reporting claim, just bullshit
3. People with hATTR have cardiac issues, deaths occur, mortality existed in Pfizer's study as well
4. The majority of SAE's on Givo resolved, again the whole altering biochemisty in a diseased state thing

Try to be a little less obvious when pretending to be an employee of Alnylam

 

1-At least you admit to RNAi creating excess mortality. Thats a start.
2-Its true. We were not transparent.
3-7 deaths on Onpattro during Apollo due to cardiac issues which is 100% of deaths on treatment drug vs. zero deaths due to cardiac issues for placebo. That really doesn't concern you??
4-Once again, we are going to minimize side-effects while overstating what our drugs are approved to do. Great

 

Hey JG,

These posts...you're embarrassing us, man. Going tit-for-tat with someone on this site isn't a good look. It makes us look like we have somethin' to hide. We'd prefer you stick with the "if you don't like it, LEAVE!" approach.

 

All true.

 

Cute how you make a bunch of posts pretending to be different people.
1- If that was true then inclisiran would have had a shitload of deaths
2- Nice comeback Potzi
3- Not really, no, all deaths were considered to be not drug related by study investigators and was approved by the FDA with those results
4- Givosiran has a broad label, try again.